BR112016020919A2 - redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc - Google Patents

redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc

Info

Publication number
BR112016020919A2
BR112016020919A2 BR112016020919A BR112016020919A BR112016020919A2 BR 112016020919 A2 BR112016020919 A2 BR 112016020919A2 BR 112016020919 A BR112016020919 A BR 112016020919A BR 112016020919 A BR112016020919 A BR 112016020919A BR 112016020919 A2 BR112016020919 A2 BR 112016020919A2
Authority
BR
Brazil
Prior art keywords
disease
treatment
snc
injury
regulatory
Prior art date
Application number
BR112016020919A
Other languages
English (en)
Inventor
BARUCH Kuti
Eisenbach-Schwartz Michal
ROSENZWEIG Neta
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of BR112016020919A2 publication Critical patent/BR112016020919A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)

Abstract

a presente invenção refere-se a uma composição farmacêutica que compreende um agente ativo que causa redução do nível de imunossupressão sistêmica em um indivíduo, para uso no tratamento de uma doença, distúrbio, condição ou lesão do snc que não inclui a doença neuroinflamatória autoimune, esclerose múltipla remitente-recorrente (emrr). a composição farmacêutica é para administração por um regime de dosagem que compreende ao menos dois cursos de terapia, cada curso de terapia compreendendo, em sequência, uma sessão de tratamento seguida de uma sessão de intervalo.
BR112016020919A 2014-03-12 2015-03-12 redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc BR112016020919A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461951783P 2014-03-12 2014-03-12
US201462030164P 2014-07-29 2014-07-29
PCT/IL2015/050265 WO2015136541A2 (en) 2014-03-12 2015-03-12 Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns

Publications (1)

Publication Number Publication Date
BR112016020919A2 true BR112016020919A2 (pt) 2018-01-23

Family

ID=53488381

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112016020919A BR112016020919A2 (pt) 2014-03-12 2015-03-12 redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc
BR112018000646A BR112018000646A2 (pt) 2014-03-12 2016-07-13 redução dos níveis ou atividade sistêmica de células t reguladoras para o tratamento de doença e lesão do snc

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112018000646A BR112018000646A2 (pt) 2014-03-12 2016-07-13 redução dos níveis ou atividade sistêmica de células t reguladoras para o tratamento de doença e lesão do snc

Country Status (13)

Country Link
US (16) US10144778B2 (pt)
EP (1) EP3116542A2 (pt)
JP (6) JP6903432B2 (pt)
KR (4) KR20200029627A (pt)
CN (2) CN114081946A (pt)
AU (5) AU2015228372B2 (pt)
BR (2) BR112016020919A2 (pt)
CA (3) CA2942245C (pt)
IL (2) IL256792B2 (pt)
MX (3) MX2016011832A (pt)
NZ (2) NZ725006A (pt)
RU (2) RU2690670C2 (pt)
WO (2) WO2015136541A2 (pt)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE034832T2 (hu) 2008-12-09 2021-12-28 Hoffmann La Roche Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
CN105026428B (zh) 2013-12-12 2018-01-16 上海恒瑞医药有限公司 PD‑l抗体、其抗原结合片段及其医药用途
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR20200029627A (ko) 2014-03-12 2020-03-18 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) * 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
WO2017042633A2 (en) * 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
IL283877B (en) 2015-05-06 2022-07-01 Snipr Tech Ltd Changing bacterial populations and microbiota adaptation
MA42043A (fr) 2015-05-07 2018-03-14 Agenus Inc Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
DK3331902T3 (da) 2015-08-07 2021-07-26 Alx Oncology Inc Konstruktioner med et sirp-alpha-domæne eller en variant deraf
KR101785155B1 (ko) * 2015-09-22 2017-10-16 국립암센터 Ｔｉｍ－３을 표적으로 하는 뇌손상 질환 치료용 조성물 및 이의 스크리닝 방법
BR112018006237A2 (pt) 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
US11447557B2 (en) 2015-12-02 2022-09-20 Agenus Inc. Antibodies and methods of use thereof
EP4306525A3 (en) * 2016-01-08 2024-03-20 Arcus Biosciences, Inc. Modulators of 5'-nucleotidase, ecto and the use thereof
DK3443009T3 (da) 2016-04-12 2021-12-13 Symphogen As Anti-tim-3-antistoffer og sammensætninger
SG11201810023QA (en) 2016-05-27 2018-12-28 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
JP7261379B2 (ja) 2016-06-20 2023-04-20 カイマブ・リミテッド 抗ｐｄ－ｌ１抗体
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
IL264049B2 (en) 2016-07-06 2023-11-01 Sperovie Biosciences Inc Compounds, preparations and methods for treating the disease
CN116640214A (zh) 2016-08-09 2023-08-25 科马布有限公司 分离抗体及其应用
IL300982B1 (en) * 2016-09-10 2024-04-01 Yeda Res & Dev Reduction of the level of regulatory T cells or their activity for the treatment of diseases and damages in the central nervous system
JP2020501508A (ja) 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
US10751414B2 (en) 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
US11166995B2 (en) 2016-11-01 2021-11-09 Osaka University Anticancer agent comprising HVJ-E and immune checkpoint protein inhibitor
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
RU2765410C2 (ru) 2016-11-30 2022-01-28 Онкомед Фармасьютикалс, Инк. Способы лечения рака, включающие связывающие tigit агенты
WO2018105630A1 (ja) * 2016-12-06 2018-06-14 国立大学法人大阪大学 新規プリオノイド病用治療薬
KR20220083863A (ko) 2017-04-05 2022-06-20 심포젠 에이/에스 Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법
MX2019012223A (es) 2017-04-13 2019-12-09 Agenus Inc Anticuerpos anti-cd137 y metodos de uso de los mismos.
EP3618863B1 (en) 2017-05-01 2023-07-26 Agenus Inc. Anti-tigit antibodies and methods of use thereof
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
JP7158677B2 (ja) * 2017-06-30 2022-10-24 小野薬品工業株式会社 溶血性レンサ球菌の菌体を含む製剤との併用療法
EP3675859A4 (en) 2017-08-31 2021-06-30 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
WO2019051489A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
EP3456819A1 (en) * 2017-09-13 2019-03-20 Trizell GmbH Regulatory macrophages for the treatment of angopathies
US20190160120A1 (en) 2017-11-29 2019-05-30 Snipr Biome Aps Dna, methods etc
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
GB2587521B (en) 2018-03-25 2023-06-21 Snipr Biome Aps Treating & preventing microbial infections
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
WO2019186559A1 (en) * 2018-03-27 2019-10-03 Raz Yirmiya Microglia modulators for use in treatment of depression
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
CN109453383A (zh) * 2018-11-12 2019-03-12 陈慧慧 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用
EP3911954A4 (en) * 2019-01-16 2022-11-02 Yeda Research and Development Co. Ltd BIOMARKERS FOR MODIFICATION OF CNS DISEASES
GB201901099D0 (en) 2019-01-27 2019-03-13 Snipr Biome Aps Methods, uses and compositions
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
GB201906668D0 (en) 2019-05-12 2019-06-26 Folium Food Science Ltd Antibacterial agents
GB201907242D0 (en) 2019-05-22 2019-07-03 Snipr Biome Aps Dna methods etc ii
US11613564B2 (en) 2019-05-31 2023-03-28 ALX Oncology Inc. Methods of treating cancer
GB201912176D0 (en) 2019-08-23 2019-10-09 Snipr Biome Aps Plasmids
JP2023503031A (ja) * 2019-11-21 2023-01-26 ベイジーン（ベイジン）カンパニー リミテッド 化学療法剤との組合せでの抗ｏｘ４０抗体による癌治療の方法
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
GB202007943D0 (en) 2020-05-27 2020-07-08 Snipr Biome Aps Products & methods
GB202015255D0 (en) 2020-09-26 2020-11-11 Snipr Biome Aps Synthetic viruses
GB202017618D0 (en) 2020-11-08 2020-12-23 Folium Food Science Ltd Antibacterial methods & cells
JP2024508658A (ja) 2021-02-04 2024-02-28 ジェヌーヴ インク． 抗ｐｄ－１抗体及びその用途
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
CA3219336A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
WO2023077016A1 (en) * 2021-10-28 2023-05-04 Baylor College Of Medicine Targeting neuronal sirpα for treatment and prevention of neurological disorders
WO2023111286A1 (en) 2021-12-17 2023-06-22 Snipr Biome Aps Nucleic acid delivery methods and compositions
CN114984219B (zh) * 2022-03-29 2023-06-27 浙江大学 Pd1抑制剂在制备心脏成纤维细胞转分化抑制剂中的用途
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies
GB202212688D0 (en) 2022-08-31 2022-10-12 Snipr Biome Aps A novel type of crispr/cas system
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
WO2000005249A2 (en) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2005046719A1 (en) * 2003-11-12 2005-05-26 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
JP5025871B2 (ja) * 2000-02-21 2012-09-12 エイチ．リュンドベック エイ／エス アミロイドの新規なダウン−レギュレート方法
US20040033497A1 (en) * 2002-08-13 2004-02-19 Alarcon-Riquelme Marta E. Polymorphisms of PD-1
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
CA2462459C (en) 2001-10-03 2007-12-18 Jack L. Strominger Copolymers for suppression of autoimmune diseases, and methods of use
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
PT2206517T (pt) 2002-07-03 2023-11-07 Tasuku Honjo Composições de imunopotenciação contendo anticorpos anti-pd-l1
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
JP2008500013A (ja) * 2003-10-03 2008-01-10 ザ ブライハム アンド ウイメンズ ホスピタル，インコーポレイテッド Ｔｉｍ−３ポリペプチド
EP2149585B1 (en) 2003-11-04 2013-08-14 Novartis Vaccines and Diagnostics, Inc. Use of antagonistic anti-CD40 monoclonal antibodies
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
EP2295588B1 (en) 2004-05-27 2018-03-07 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses thefor
GB0503434D0 (en) * 2005-02-18 2005-03-30 Senexis Ltd Amyloid-binding peptides, analogues and uses thereof
ES2427646T5 (es) 2005-05-09 2017-08-22 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
MX2007015942A (es) * 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
CA2627891A1 (en) 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
EP2081961A2 (en) 2006-11-15 2009-07-29 The Brigham and Women's Hospital, Inc. Therapeutic uses of tim-3 modulators
US20100203010A1 (en) * 2007-03-28 2010-08-12 Biogen Idec Inc. Modulation of tumor microenvironment
EP4119579A1 (en) * 2007-05-31 2023-01-18 Genmab A/S Stable igg4 antibodies
RS53072B (en) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1
PT2238166E (pt) 2007-10-05 2014-02-11 Genentech Inc Utilização do anticorpo anti-amilóide beta em doenças oculares
WO2009094273A2 (en) 2008-01-15 2009-07-30 Yale University Compositions and methods for adoptive and active immunotherapy
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
PL2342226T3 (pl) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
CN102216448A (zh) * 2008-11-13 2011-10-12 分子医学研究院 Foxp3+天然杀伤t细胞及免疫相关疾病的治疗
EP3153524A1 (en) 2008-12-03 2017-04-12 Genmab A/S Antibody variants having modifications in the constant region
US8741295B2 (en) 2009-02-09 2014-06-03 Universite De La Mediterranee PD-1 antibodies and PD-L1 antibodies and uses thereof
EP2496594B1 (en) 2009-11-06 2018-01-17 The J. David Gladstone Institutes Methods and compositions for modulating tau levels
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
US8835613B2 (en) 2010-03-12 2014-09-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services β-mannosylceramide and stimulation of NKT cell anti-tumor immunity
US10745467B2 (en) * 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
WO2012075291A1 (en) * 2010-12-01 2012-06-07 The Children's Hospital Of Philadelphia Compositions and methods for treating foxp3+ treg related diseases
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
CA2830882C (en) 2011-03-22 2021-03-16 Dinesh Barawkar Substituted fused tricyclic compounds, compositions and medicinal applications thereof
LT2691112T (lt) 2011-03-31 2018-07-25 Merck Sharp & Dohme Corp. Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai
MX338353B (es) 2011-04-20 2016-04-13 Medimmune Llc Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
CN107915775B (zh) * 2011-07-11 2022-07-12 伊克诺斯科学公司 结合ox40的抗体及其用途
WO2013022738A1 (en) * 2011-08-05 2013-02-14 Bioasis Technologies, Inc. P97 fragments with transfer activity
EP3939613A1 (en) 2011-08-11 2022-01-19 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
US9364542B2 (en) 2011-10-28 2016-06-14 Excelse Bio, Inc. Protein formulations containing amino acids
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20150086584A1 (en) 2012-03-22 2015-03-26 University Of Miami Multi-specific binding agents
CN104394877B (zh) 2012-05-08 2017-11-28 约翰·霍普金斯大学 用于输注短暂植入的同种异体淋巴细胞的选定群体来治疗癌症的方法和组合物
NZ622452A (en) 2012-06-21 2017-10-27 Compugen Ltd Lsr antibodies, and uses thereof for treatment of cancer
CA2877533C (en) 2012-06-22 2022-08-16 The Trustees Of Dartmouth College Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
US10513540B2 (en) * 2012-07-31 2019-12-24 The Brigham And Women's Hospital, Inc. Modulation of the immune response
WO2014028502A1 (en) 2012-08-13 2014-02-20 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014037952A1 (en) * 2012-09-10 2014-03-13 Yeda Research And Development Co. Ltd At The Weizmann Institute Of Science Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia
EP2897962A1 (en) 2012-09-21 2015-07-29 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
AU2013330433B2 (en) 2012-10-09 2016-06-16 Sanbio, Inc. Methods and compositions for treatment of retinal degeneration
KR102229873B1 (ko) 2012-10-12 2021-03-19 더 브리검 앤드 우먼즈 하스피털, 인크. 면역 반응의 향상
MX365527B (es) 2012-10-24 2019-06-06 Us Health Formas il-15r alfa, celulas que expresan las formas de il-15 alfa, y usos terapeuticos de il-15r alfa y complejos il-15/il-15r.
JP6374392B2 (ja) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
WO2014074852A1 (en) 2012-11-09 2014-05-15 President And Fellows Of Harvard College Compositions and methods for modulating an immune response
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
CA2895284A1 (en) 2013-02-07 2014-08-14 Immunomedics, Inc. Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
PT2961388T (pt) 2013-03-01 2019-07-11 Astex Pharmaceuticals Inc Combinações de fármacos
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
SG11201507247WA (en) 2013-03-13 2015-10-29 Oncoceutics Inc Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
WO2014186035A1 (en) 2013-03-14 2014-11-20 Curadev Pharma Private Ltd. Inhibitors of the kynurenine pathway
AU2014241843B2 (en) 2013-03-14 2019-05-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
EP3607974A1 (en) 2013-03-15 2020-02-12 The Trustees of The University of Pennsylvania Cancer vaccines and methods of treatment using the same
US20140377253A1 (en) 2013-03-15 2014-12-25 Abbvie Biotherapeutics Inc. Fc variants
WO2014145907A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins
EA201591559A1 (ru) 2013-03-15 2016-03-31 Дана-Фарбер Кэнсер Инститьют, Инк. Терапевтические пептиды
US10047137B2 (en) 2013-04-05 2018-08-14 Versitech Limited Antibodies against novel PD1 isoforms and uses thereof
CN105339389B (zh) 2013-05-02 2021-04-27 安奈普泰斯生物有限公司 针对程序性死亡-1(pd-1)的抗体
AU2014262469B2 (en) 2013-05-10 2019-11-14 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CA2953287A1 (en) 2013-06-19 2014-12-24 Massachusetts Institute Of Technology In vivo targeting of cells with ligand-conjugated particles
US9616129B2 (en) 2013-06-22 2017-04-11 Nitor Therapeutics Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
RS60826B1 (sr) 2013-07-16 2020-10-30 Hoffmann La Roche Postupci lečenja kancera upotrebom antagonista vezivanja pd-1 ose i tigit inhibitora
EP3030575B1 (en) 2013-08-08 2018-07-11 Cytune Pharma Il-15 and il-15r-alpha sushi domain based modulokines
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
KR20160055819A (ko) 2013-08-22 2016-05-18 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 암 및 바이러스 감염을 치료하기 위한 면역수용체 조절
SG11201601285XA (en) 2013-08-22 2016-03-30 Queensland Inst Med Res Immunoreceptor modulation for treating cancer and viral infections
US10077305B2 (en) 2013-09-10 2018-09-18 Medimmune Limited Antibodies against PD-1 and uses thereof
CA2922805A1 (en) * 2013-09-11 2015-03-19 Compugen Ltd. Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
JP6623353B2 (ja) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｐｄ−１抗体並びにその治療及び診断のための使用
WO2015061752A1 (en) 2013-10-25 2015-04-30 Pharmacyclics, Inc. Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
CN104558177B (zh) 2013-10-25 2020-02-18 苏州思坦维生物技术股份有限公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
WO2015069697A2 (en) 2013-11-05 2015-05-14 Nkt Therapeutics Inc. Combination therapy
WO2015084721A1 (en) 2013-12-02 2015-06-11 Tabaczynski David A Inhibition of isoprenoid biosynthetic pathways to treat autoimmune disorders
WO2015082499A2 (en) 2013-12-03 2015-06-11 Iomet Pharma Ltd Pharmaceutical compound
BR112016012358A2 (pt) 2013-12-06 2017-09-26 Dana Farber Cancer Inst Inc peptídios terapêuticos
CN105026428B (zh) 2013-12-12 2018-01-16 上海恒瑞医药有限公司 PD‑l抗体、其抗原结合片段及其医药用途
PE20210107A1 (es) 2013-12-17 2021-01-19 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
RS61223B1 (sr) 2013-12-20 2021-01-29 Hutchinson Fred Cancer Res Označeni himerni efektorski molekuli i njihovi receptori
BR112016015140A2 (pt) 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
WO2015103602A1 (en) 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2017042633A2 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US10618963B2 (en) * 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) * 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
KR20200029627A (ko) 2014-03-12 2020-03-18 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
PL3322424T3 (pl) * 2015-07-16 2024-03-04 Yeda Research And Development Co., Ltd. Zastosowanie centralnych limfocytów t pamięci przeciwko stronie trzeciej
CN115960235A (zh) 2015-08-28 2023-04-14 艾利妥 抗siglec-7抗体及其使用方法
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN109563171B (zh) 2016-06-20 2023-09-19 F-星治疗有限公司 结合pd-l1和lag-3的结合分子
JP7261379B2 (ja) 2016-06-20 2023-04-20 カイマブ・リミテッド 抗ｐｄ－ｌ１抗体
IL268126B2 (en) * 2017-01-18 2024-02-01 Yeda Res & Dev Genetically engineered Veto cells and their uses in immunotherapy
EP3911954A4 (en) * 2019-01-16 2022-11-02 Yeda Research and Development Co. Ltd BIOMARKERS FOR MODIFICATION OF CNS DISEASES
EP3725370A1 (en) * 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease

Also Published As

Publication number Publication date
US20180111997A1 (en) 2018-04-26
IL247747B (en) 2020-08-31
WO2017009829A1 (en) 2017-01-19
WO2015136541A3 (en) 2015-11-12
AU2022202797A1 (en) 2022-05-19
IL256792B1 (en) 2023-07-01
JP2017512771A (ja) 2017-05-25
BR112018000646A2 (pt) 2018-12-11
US20160319021A1 (en) 2016-11-03
US20210221888A1 (en) 2021-07-22
US9982050B2 (en) 2018-05-29
US9982051B2 (en) 2018-05-29
MX2016011832A (es) 2017-05-12
AU2020201602A1 (en) 2020-03-19
US20190185563A1 (en) 2019-06-20
US9512225B2 (en) 2016-12-06
US20160297880A1 (en) 2016-10-13
CA2942245C (en) 2021-11-02
AU2018220155A1 (en) 2018-09-13
JP2018524362A (ja) 2018-08-30
CN106687125B (zh) 2021-12-14
US9534052B2 (en) 2017-01-03
AU2016293498A1 (en) 2018-03-01
US9982048B2 (en) 2018-05-29
US20160008463A1 (en) 2016-01-14
CA2942245A1 (en) 2015-09-17
EP3116542A2 (en) 2017-01-18
US20210188977A1 (en) 2021-06-24
JP6867367B2 (ja) 2021-04-28
KR20200029627A (ko) 2020-03-18
US11884727B2 (en) 2024-01-30
JP2020040976A (ja) 2020-03-19
CN106687125A (zh) 2017-05-17
US20180111998A1 (en) 2018-04-26
US20180118826A1 (en) 2018-05-03
IL256792A (en) 2018-03-29
NZ725006A (en) 2019-11-29
RU2018104962A (ru) 2019-08-13
RU2690670C2 (ru) 2019-06-05
RU2016139974A3 (pt) 2018-10-12
KR20160133510A (ko) 2016-11-22
US20170240634A1 (en) 2017-08-24
AU2018220155B2 (en) 2019-12-05
US20240182566A1 (en) 2024-06-06
US10144778B2 (en) 2018-12-04
JP6903432B2 (ja) 2021-07-14
JP2022163730A (ja) 2022-10-26
US10214585B2 (en) 2019-02-26
KR20180030128A (ko) 2018-03-21
IL247747A0 (en) 2016-11-30
MX2021009611A (es) 2021-09-08
AU2020201602B2 (en) 2022-02-03
KR102248804B1 (ko) 2021-05-11
US9512227B2 (en) 2016-12-06
AU2016293498B2 (en) 2022-01-13
MX2018000466A (es) 2018-11-09
US9982047B2 (en) 2018-05-29
US20190112371A1 (en) 2019-04-18
US10981989B2 (en) 2021-04-20
US20160000909A1 (en) 2016-01-07
JP2023089119A (ja) 2023-06-27
KR20230097209A (ko) 2023-06-30
NZ747418A (en) 2023-05-26
US20160311905A1 (en) 2016-10-27
CN114081946A (zh) 2022-02-25
IL256792B2 (en) 2023-11-01
AU2015228372B2 (en) 2018-05-31
WO2015136541A2 (en) 2015-09-17
RU2016139974A (ru) 2018-04-12
US9856318B2 (en) 2018-01-02
CA2991981A1 (en) 2017-01-19
RU2741366C2 (ru) 2021-01-25
CA3129892A1 (en) 2015-09-17
US9982049B2 (en) 2018-05-29
JP2021107412A (ja) 2021-07-29
US10961309B2 (en) 2021-03-30
US20180111999A1 (en) 2018-04-26
AU2015228372A1 (en) 2016-10-27
RU2018104962A3 (pt) 2020-02-04
US11884728B2 (en) 2024-01-30
US20180105592A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
BR112016020919A2 (pt) redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc
MX2018003028A (es) Reduccion de los niveles o de la actividad de los linfocitos t reguladores sistemicos para el tratamiento de enfermedades y lesiones del sistema nervioso central (snc).
WO2017042633A3 (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
BR112017011536A2 (pt) terapias de combinação
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112019002538A2 (pt) uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral
BR112016012506A2 (pt) Combinações farmacêuticas, seus usos, e uso de um portador de dados
EP4279135A3 (en) Use of a vegf antagonist to treat diabetic retinopathy
BR112017022101A2 (pt) composição farmacêutica para prevenção e/ou tratamento de dermatite atópica contendo antagonista de il-31 como ingrediente ativo
CR20170259A (es) Terapias de envenenamiento y composiciones farmacéuticas, sistemas y equipos relacionados
BR112018003461A2 (pt) dispositivo de seringa, e método para administrar uma dose terapêutica de pelo menos um medicamento
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
BR112017005209A2 (pt) compostos moduladores de pirrolopiridina substituída por metila e trifluorometila de rorc2 e seu uso
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
HRP20211824T1 (hr) Modulatori aktivnosti komplementa
BR112016001781A2 (pt) inibidores de rorc2 e métodos de uso dos mesmos
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.
BR112016023450A2 (pt) uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce
BR112016030064A2 (pt) ?métodos de tratamento de câncer, de aumentar a eficácia de um tratamento de câncer, de atrasar e/ou prevenir o desenvolvimento de câncer, de tratamento de um indivíduo, de aumentar a sensibilidade a um agente de terapia, de prolongar o período de uma sensibilidade de agente de terapia e de prolongar a duração da resposta a uma terapia?
BR112022011388A2 (pt) Métodos para tratar ou prevenir asma alérgica administrando um antagonista de il-33 e/ou um antagonista de il-4r
BR112021025291A2 (pt) Dispositivos de contenção de medicamento e composições associadas
AR116592A1 (es) Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib
WO2016154143A8 (en) Compositions and methods for treating copd and other inflammatory conditions
BR112019001808A2 (pt) composição farmacêutica anticâncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]